"The effect of Olanzapine on chemotherapy induced nausea and vomiting"

The effect of Olanzapine on chemotherapy induced nausea and vomiting in patients with cancer : A randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170814035697N3

Enrollment

150

Registered

2018-03-16

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy induced nausea and vomiting. Nausea and vomiting

Interventions

Intervention 1: intervention group: routine treatment + olanzapine tablets with a dose of 5 mg for patients less than 60 kg and 10 mg for patients over 60 kg one day before the start of chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years old. Chemotherapy due to cancer for the first time

Exclusion criteria

Exclusion criteria: Having allergic to olanzapine Patients under Radiotherapy Patients with surgical history Diabetic patients hyperlipidemia

Design outcomes

Primary

Measure	Time frame
The nausea and vomiting severity. Timepoint: The before, first, third and fifth days of chemotherapy. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamdolah Sharifi

Oroumia University of Medical Sciences

Sharifi_md1992@yahoo.com+98 44 3223 4897

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026